US Senate asks Novartis to shed light on data manipulation allegations
The one-time treatment for spinal muscular atrophy costs $2.1 million (CHF2.1 million).
Keystone / Yannick Bailly
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma – the world’s most expensive treatment.
Novartis has been accused of withholding information about manipulated data during early testing of Zolgensma, a one-time $2.1 million (CHF2.1 million) treatment for spinal muscular atrophy (SMA), the leading genetic cause of death in infants. The treatment was approved by the US Food and Drug Administration (FDA) in May.
Novartis said its subsidiary in California began investigating the alleged data manipulation for Zolgensma as soon as it learned about it. The company claims that it shared the information with the FDA as soon as it had the interim conclusions.
The chairman of the US Senate Finance Committee, Chuck Grassley, wants to have access to internal reports and to know exactly when the group became aware of the data manipulation. The Basel-based pharmaceutical giant has until August 23 to shed light on the situation. Novartis has acknowledged receipt of this request.
Despite the allegations, the FDA reported last week that it retains full confidence in the new treatment. However, it plans to take the case to court, as the pharmaceutical group was aware of the problem before receiving the green light to market it at the end of May.
“The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties,” said an FDA statement last weekExternal link.
Novartis has blamed several employees of its subsidiary Avexis, but according to several analysts this case could cost it dearly. Zolgensma has yet to receive the green light from authorities in the European Union and Japan.
More
More
Novartis rejects suspected data manipulation in US
This content was published on
Swiss pharma giant Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to US authorities.
Andrew Ridgeley back in Swiss Alps for BBC’s ‘Last Christmas’ documentary
This content was published on
Wham! star Andrew Ridgeley fondly recalls filming the hit 'Last Christmas' in the Swiss village of Saas Fee, describing it as the perfect location.
This content was published on
The world’s steepest cable car, connecting the villages of Stechelberg and Mürren in the Bernese Oberland, began welcoming passengers on Saturday.
Swiss Federal Court upholds ban on Mexican food brand Bimbo’s trademark
This content was published on
The Mexican food company “Bimbo” has been barred from registering its trademark in Switzerland due to the term's discriminatory connotations in German.
Climate change could slash company profits by 7% by 2035, says WEF
This content was published on
Companies that ignore climate risks like extreme heat could face annual profit losses of up to 7% by 2035. This is nearly half the decline seen during the coronavirus pandemic.
EU-Swiss negotiations near conclusion amid ‘very intense’ talks
This content was published on
Ongoing negotiations between Switzerland and the EU are at a delicate stage, with talks continuing and ‘very intense,’ a Commission spokesperson said.
Swiss government rejects proposed super-rich inheritance tax
This content was published on
Switzerland’s government rejected a proposal to jack up inheritance taxes on the super rich, diminishing the chances of the plan passing in a national vote.
Swiss government wants to ban swastika in crackdown on extremist symbols
This content was published on
The Federal Council wants to ban the Nazis’ swastika emblem in public as well as other symbols associated with the Third Reich. Anyone who flouted the law would be fined CHF200 in future.
Switzerland greenlights use of self-driving cars on motorways from March 2025
This content was published on
From March 2025, drivers will be allowed to use self-driving technology on Swiss motorways and let go of their steering wheel.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
Push for drug pricing transparency strikes a nerve with industry
This content was published on
The 72nd World Health Assembly opens on Monday, but a draft resolution to end secrecy around drug pricing has already struck a nerve.
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.